Prescribing Information Summary of Product Characteristics
digoxin immune fab digifab logo DIGIFab

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

Order DIGIFab®
01865 904141

Mechanism of Action

DIGIFab® Rapidly Binds
and Neutralises Digoxin1,2

  • DIGIFab® neutralises free digoxin within minutes to resolve the cardiotoxic effects and other clinical manifestations of life-threatening digoxin toxicity.2,6*

Results from a prospective, multicentre safety, efficacy, and pharmacokinetic study in patients presenting with life-threatening digoxin toxicity (N=15) conducted in the United States and Finland. Results were compared with historical data on Digibind®. Patients received doses of DIGIFab® based on its theoretical binding capacity for   digoxin and based on the known amount of digoxin ingested or on blood concentrations of digoxin at the time of admission.

References

  1. DIGIFab Digoxin Immune Fab (ovine) [summary of product characteristics]. Protherics UK Limited; 2017.
  2. Ward SB, Sjostrom L, Ujhelyi MR. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ther Drug Monit. 2000;22(5):599-607.
  3. Levine MD, O’Connor A. Digitalis (cardiac glycoside) poisoning. UpToDate. Updated January 2020. https://www.uptodate.com/contents/digitalis-cardiac-glycoside-poisoning. Accessed December 2023.
  4. Goldberger AL, Traub SJ. Cardiac arrhythmias due to digoxin toxicity. Updated January 2020. https://www.uptodate.com/contents/cardiac-arrhythmias-due-to-digoxin-toxicity. Accessed December 2023.
  5. Schmidt TA, Kjeldsen K. Enhanced clearance of specifically bound digoxin from human myocardial and skeletal muscle samples by specific digoxin antibody fragments: subsequent complete digitalis glycoside receptor (Na,K-ATPase) quantification. J Cardiovasc Pharmacol. 1991;17(4):670-677.
  6. Data on file. BTG International Ltd.